Lipid nanoparticles (LNPs) have emerged across the pharmaceutical industry as promising
vehicles to deliver a variety of therapeutics. Currently in the spotlight as vital components of …

Lipid nanoparticles (LNPs) play an important role in mRNA vaccines against COVID-19. In
addition, many preclinical and clinical studies, including the siRNA-LNP product, Onpattro® …

Messenger RNA (mRNA) has emerged as a new category of therapeutic agent to prevent
and treat various diseases. To function in vivo, mRNA requires safe, effective and stable …

Conspectus Lipid nanoparticles (LNPs) are a type of lipid vesicles that possess a
homogeneous lipid core. These vesicles are widely used in small-molecule drug and …

mRNA lipid nanoparticles (LNPs) are at the forefront of nucleic acid intracellular delivery, as
exemplified by the recent emergency approval of two mRNA LNP-based COVID-19 …

RNA therapeutics show a significant breakthrough for the treatment of otherwise incurable
diseases and genetic disorders by regulating disease-related gene expression. The …

The success of mRNA vaccines during the COVID-19 pandemic has greatly accelerated the
development of mRNA therapy. mRNA is a negatively charged nucleic acid that serves as a …

Lipid nanoparticles have attracted significant interests in the last two decades, and have
achieved tremendous clinical success since the first clinical approval of Doxil in 1995. At the …

Lipid nanoparticles (LNPs) have shown remarkable success in delivering genetic materials
like COVID-19 LNP vaccines, such as mRNA-1273/SpikeVax by Moderna and …

Conspectus After decades of extensive fundamental studies and clinical trials, lipid
nanoparticles (LNPs) have demonstrated effective mRNA delivery such as the Moderna and …